<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Increasing evidence indicates that <z:chebi fb="1" ids="24261">glucocorticoids</z:chebi> (GCs), produced in response to physical/emotional stressors, can exacerbate brain damage resulting from <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> and severe <z:hpo ids='HP_0001250'>seizure</z:hpo> activity </plain></SENT>
<SENT sid="1" pm="."><plain>However, much of the supporting evidence has come from studies employing nonphysiological paradigms in which adrenalectomized rats were compared with those exposed to constant GC concentrations in the upper physiological range </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0002637'>Cerebral ischemia</z:hpo> and <z:hpo ids='HP_0001250'>seizures</z:hpo> can induce considerable GC secretion </plain></SENT>
<SENT sid="3" pm="."><plain>We now present data from experiments using <z:chebi fb="0" ids="44241">metyrapone</z:chebi> (an 11-beta-hydroxylase inhibitor of GC production), which demonstrate that the GC stress-response worsens subsequent brain damage induced by <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and <z:hpo ids='HP_0001250'>seizures</z:hpo> in rats </plain></SENT>
<SENT sid="4" pm="."><plain>Three different paradigms of brain injury were employed: middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) model of focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>; four-vessel occlusion (4VO) model of transient global forebrain <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>; and <z:chebi fb="0" ids="31746">kainic acid</z:chebi> (KA)-induced (<z:hpo ids='HP_0001250'>seizure</z:hpo>-mediated) excitotoxic damage to hippocampal CA3 and CA1 neurons </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="44241">Metyrapone</z:chebi> (200 mg/kg body wt) was administered systemically in a single i.p. bolus 30 min prior to each insult </plain></SENT>
<SENT sid="6" pm="."><plain>In the MCAO model, <z:chebi fb="0" ids="44241">metyrapone</z:chebi> treatment significantly reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volume and also preserved cells within the <z:mpath ids='MPATH_124'>infarct</z:mpath> </plain></SENT>
<SENT sid="7" pm="."><plain>In the 4VO model, <z:hpo ids='HP_0002529'>neuronal loss</z:hpo> in region CA1 of the hippocampus was significantly reduced in rats administered <z:chebi fb="0" ids="44241">metyrapone</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0001250'>Seizure</z:hpo>-induced damage to hippocampal pyramidal neurons (assessed by cell counts and immunochemical analyses of cytoskeletal alterations) was significantly reduced in rats administered <z:chebi fb="0" ids="44241">metyrapone</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>Measurement of plasma levels of <z:chebi fb="0" ids="16827">corticosterone</z:chebi> (the species-typical GC of rats) after each insult showed that <z:chebi fb="0" ids="44241">metyrapone</z:chebi> significantly suppressed the injury-induced rise in levels of circulating <z:chebi fb="0" ids="16827">corticosterone</z:chebi> </plain></SENT>
<SENT sid="10" pm="."><plain>These findings indicate that endogenous <z:chebi fb="0" ids="16827">corticosterone</z:chebi> contributes to the basal level of brain injury resulting from <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> and excitotoxic <z:hpo ids='HP_0001250'>seizure</z:hpo> activity and suggest that drugs that suppress <z:chebi fb="1" ids="24261">glucocorticoid</z:chebi> production may be effective in reducing brain damage in <z:hpo ids='HP_0001297'>stroke</z:hpo> and <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e> patients </plain></SENT>
</text></document>